FGF23 and Hypercalciuria: In mouse models, canagliflozin demonstrated a significant rise in markers of bone resorption, particularly carboxy-terminal telopeptide of collagen type 1 (CTX), with consequent hypercalciuria and higher circulating serum levels of Fibroblast Growth Factor 23 (FGF-23), with evident deterioration of trabecular bone mass and marked deficits in cortical and trabecular bone architecture [44,45].